22 completed, 3 recruiting, 3 terminated, 1 active not recruiting. 30 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 30 | Completed 22, Recruiting 3, Terminated 3, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
Follow Anaplastic Oligodendroglioma: new trials by email Literature Review of Anaplastic Oligodendroglioma trials Research Report on Anaplastic Oligodendroglioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas Biospecimen Collection, Eflornithine, Lumbar Puncture - Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 33 | 2026-06-23 | 2026-06-24 |
| A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma PCI 24781, Temozolomide - Recurrent High Grade Glioma, Anaplastic Astrocytoma | Phase 1 | Recruiting | University of Nebraska | 24 | 2023-06-26 | 2026-09-14 |
| A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years - Medulloblastoma, Glioblastoma Multiforme | Phase 1 | Active not recruiting | Children's Oncology Group | 35 | 2022-07-01 | 2026-06-02 |
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms ONC206 - Central Nervous System Neoplasms, Glioblastoma | Phase 1 | Recruiting | Jazz Pharmaceuticals | 102 | 2020-10-26 | 2026-10-23 |
| INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas INCB7839 - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 13 | 2020-07-27 | 2026-10-01 |
| Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg - High Grade Glioma, Anaplastic Astrocytoma | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 7 | 2019-12-06 | 2023-10-06 |
| SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Gemcitabine, ribociclib, sonidegib - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Completed | St. Jude Children's Research Hospital | 68 | 2018-03-05 | 2024-05-31 |
| Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children Polio/Rhinovirus Recombinant (PVSRIPO) - Malignant Glioma, Anaplastic Astrocytoma | Phase 1 | Completed | Istari Oncology, Inc. | 8 | 2017-11-07 | 2024-04-08 |
| Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma Neural stem cells loaded with an oncolytic adenovirus - Glioma, Anaplastic Astrocytoma | Phase 1 | Completed | Northwestern University | 12 | 2017-04-24 | 2023-01-20 |
| RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas RRx-001 dose escalation with TMZ + RT, Radiation, Fixed dose Temozolomide (75 mg/m2) - Glioblastoma, Oligodendroglioma | Phase 1 | Completed | EpicentRx, Inc. | 19 | 2017-02-14 | 2022-05-16 |
| Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma Laboratory Biomarker Analysis, Lapatinib, Lapatinib Ditosylate - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2016-11-07 | 2024-11-06 |
| Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Mebendazole - Medulloblastoma, Astrocytoma, Grade III | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 16 | 2016-05-01 | 2022-06-23 |
| Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas Cytoreductive surgery, Perifosine, Temsirolimus - Brain Tumor, Recurrent, Glioblastoma | Phase 1 | Completed | Andrew B Lassman, MD | 10 | 2014-12-08 | 2023-05-25 |
| Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma ascorbic acid, temozolomide, quality-of-life assessment - Anaplastic Astrocytoma, Anaplastic Oligodendroglioma | Phase 1 | Terminated | University of Nebraska | 4 | 2014-06-16 | 2023-11-24 |
| Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor Toca 511, Toca FC - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 | Completed | Tocagen Inc. | 17 | 2014-02-01 | 2018-05-21 |
| p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors azurin-derived cell-penetrating peptide p28 - Teratoid Tumor, Atypical, Choroid Plexus Neoplasms | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 18 | 2013-08-01 | 2017-08-07 |
| Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas AXL1717 - Glioblastoma, Gliosarcoma | Phase 1 / Phase 2 | Terminated | Rush University Medical Center | 10 | 2012-12-01 | 2023-05-22 |
| Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Laboratory Biomarker Analysis, Montanide ISA-51/Survivin Peptide Vaccine, Sargramostim - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 1 | Completed | Roswell Park Cancer Institute | 9 | 2012-09-05 | 2017-02-27 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2012-03-01 | 2016-10-04 |
| Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor Toca 511 vector, Toca FC - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 | Completed | Tocagen Inc. | 58 | 2012-02-01 | 2018-05-21 |
Showing 20 of 30. Sign in to see all of them.
Oligodendroglioma (30) · Astrocytoma (29) · Glioblastoma (29) · Glioma (23) · Brain Neoplasms (12) · Gliosarcoma (12) · Ependymoma (7) · Medulloblastoma (6) · Meningioma (4) · Neuroectodermal Tumors, Primitive (4) · Central Nervous System Neoplasms (3) · Lymphoma, Follicular (3) · Brain Stem Neoplasms (2) · Choroid Plexus Neoplasms (2) · Diffuse Intrinsic Pontine Glioma (2)
Neoplasms by Histologic Type (30) · Neoplasms, Glandular and Epithelial (30) · Neoplasms, Nerve Tissue (30) · Neoplasms, Germ Cell and Embryonal (29) · Neuroectodermal Tumors (29) · Neoplasms (28) · Neoplasms, Neuroepithelial (28) · Neoplasms by Site (17) · Nervous System Diseases (17) · Nervous System Neoplasms (17) · Brain Diseases (16) · Central Nervous System Diseases (16) · Central Nervous System Neoplasms (14) · Glioma (7) · Brain Neoplasms (4)
Flucytosine (3) · Temozolomide (3) · Magnetic Resonance Spectroscopy (2) · vocimagene amiretrorepvec (2) · (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol (1) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Ascorbic Acid (1) · Carboplatin (1) · Colony-Stimulating Factors (1) · Cytoreduction Surgical Procedures (1) · Eflornithine (1) · Etoposide (1) · Filgrastim (1) · Gemcitabine (1) · Genetic Engineering (1)
Tocagen Inc. (3) · Mayo Clinic (2) · National Cancer Institute (NCI) (2) · Pediatric Brain Tumor Consortium (2) · Roswell Park Cancer Institute (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University of Nebraska (2) · Andrew B Lassman, MD (1) · Annick Desjardins (1) · Children's Oncology Group (1) · City of Hope Medical Center (1) · EpicentRx, Inc. (1) · INSYS Therapeutics Inc (1) · Istari Oncology, Inc. (1) · Jazz Pharmaceuticals (1)
United States (29) · Canada (1) · Switzerland (1)
Asha Das, MD (3) · Andrew B. Lassman, MD (1) · Annick Desjardins, MD (1) · Behnam Badie (1) · Bryan Oronsky (1) · Clare Twist, MD (1) · Daniel Landi, MD (1) · Darell Bigner, MD, PhD (1) · Edward A Neuwelt (1) · Eric Thompson, MD (1) · Evanthia Galanis (1) · Giles W. Robinson, MD (1) · Katherine E Warren, M.D. (1) · Kenneth J Cohen, MD (1) · Kunle Odunsi (1)
PMID 24786603, PMID 29762717, PMID 34214495, PMID 35417530, PMID 37004712, PMID 38182653, PMID 38215438, PMID 38216554, PMID 40132910, PMID 40225909, PMID 9390198
P30CA016056 (2), UM1CA081457 (2), UM1CA137443 (2), P30CA015083 (1), P30CA036727 (1), P50CA108961 (1), P50CA221747 (1), R01CA125244 (1), R01CA158318 (1), U01CA081457 (1), U01CA137443 (1)